Feature

Arrivo developing novel medicines to target hard-to-treat diseases at their source

Closely-held Arrivo BioVentures is developing novel, first-in-class medicines that target the underlying causes of diseases with high unmet need, aiming to achieve meaningful patient outcomes that extend and improve the...

June 10, 2025

Feature

JVP Labs redefining congestive heart failure monitoring

Closely held JVP Labs is developing the only non-invasive, real-time cardiac filling pressure monitoring solution for managing congestive heart failure (CHF) patients—for both in the hospital and at home.

June 3, 2025

Feature

Eledon leading a paradigm shift in immunosuppression therapy in organ transplantation

Eledon Pharmaceuticals (NASDAQ: ELDN) is pioneering a potential breakthrough in immunosuppression therapy aimed at extending the longevity of transplanted organs and enhancing the overall health and quality of life for...

May 27, 2025

Feature

Longhorn impacting global health challenges by tackling bacterial toxins with vaccine and diagnostics solutions

Closely held Longhorn Vaccines and Diagnostics is developing peptide vaccines and monoclonal antibodies aimed at preventing and reducing the global burden of medical conditions caused by key bacterial toxins, including...

May 20, 2025

NEWS

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Arrivo developing novel medicines to target hard-to-treat diseases at their source

JVP Labs redefining congestive heart failure monitoring

Eledon leading a paradigm shift in immunosuppression therapy in organ transplantation

Longhorn impacting global health challenges by tackling bacterial toxins with vaccine and diagnostics solutions

NEWS

BioRestorative reports compelling early data for FDA-Fast-Tracked BRTX-100 for cLDD

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Adial’s lead AUD candidate advances toward Phase 3 trial

Beacon appoints Dr. Daniel Chung as CMO

Laura Conquergood joins Baylis as CEO

First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction

BioRestorative welcomes renowned industry leader, Sandy Lipkins, to BRTX team

Citius and Cardinal sign distribution agreement

Leef acquires New York License

Just a few of the companies we’ve highlighted along the way

Subscribe